G9pharma co., LTD reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 0.00001 million. Net loss was KRW 7,024.19 million compared to KRW 6,149.74 million a year ago. Basic loss per share from continuing operations was KRW 1,880 compared to KRW 2,760 a year ago. Diluted loss per share from continuing operations was KRW 1,880 compared to KRW 2,760 a year ago. Basic loss per share was KRW 94 compared to KRW 138 a year ago.
For the nine months, sales was KRW 0.00001 million. Net loss was KRW 31,929.06 million compared to KRW 23,528.14 million a year ago. Basic loss per share from continuing operations was KRW 8,980 compared to KRW 10,580 a year ago. Diluted loss per share from continuing operations was KRW 8,980 compared to KRW 10,580 a year ago. Basic loss per share was KRW 449 compared to KRW 529 a year ago.